NCT06446804

Follow-up of Migraine Patients on Eptinezumab

Feedback on the Use of Eptinezumab: Efficacy at 6 Months in Severe Migraine

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 60 (actual)
• Sponsor: Centre Hospitalier Universitaire de Nīmes · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The October 2022 Transparency Commission considers that VYEPTI (eptinezumab) is a treatment option for patients suffering from severe migraine with at least 8 migraine days per month, who have failed at least two prophylactic treatments and have no cardiovascular impairment. Since the beginning of 2023, eptinezumab has been available in France as an inpatient treatment prescribed by a migraine neurologist in a growing number of centres. The Saint-Denis Hospital and the Nîmes University Hospital are among the first centres to have started. The investigators from these 2 centres have therefore decided to pool their data to provide the first French feedback on its effectiveness.

Conditions

• Migraine

Interventions

Type	Name	Description
OTHER	None, pure observationnal study	Pure observatonnal study

Timeline

• Start date: 2024-06-01
• Primary completion: 2024-08-31
• Completion: 2024-08-31
• First posted: 2024-06-06
• Last updated: 2024-11-01

Locations

2 sites across 1 country: France